论文信息 - Progressive multi‐focal leucoencephalopathy among ibrutinib‐treated persons with chronic lymphocytic leukaemia

Progressive multi‐focal leucoencephalopathy among ibrutinib‐treated persons with chronic lymphocytic leukaemia

Wang: No relevant conflicts of interest. Morrissette: No relevant conflicts of interest. Lieberman: No relevant conflicts of interest. Timlin: No relevant conflicts of interest. Schuster: Nordic Nanovector: Membership on an entity’s Board of Directors or advisory committees; Janssen: Research Funding; Novartis: Research Funding; Genentech: Consultancy; Gilead: Research Funding; Hoffman-LaRoche: Research Funding; Celgene: Consultancy, Research Funding; Phamacyclics: Consultancy, Research Funding. Mato: Gilead: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Pronai Pharmaceuticals: Research Funding; Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy; Celgene Corporation: Consultancy, TG Therapeutics: Research Funding; Acerta: Research Funding. Jie Wang Jennifer Morrissette David B. Lieberman Colleen Timlin Stephen J. Schuster Anthony R. Mato Center for CLL, and Center for Personalized Diagnostics, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA E-mail: anthony.mato@uphs.upenn.edu

[1] Jeffrey A Jones,et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. , 2015, JAMA oncology.

[2] C. Bennett,et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project , 2014, Cancer.

[3] J. Sejvar,et al. PML diagnostic criteria , 2013, Neurology.

[4] D. West,et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2009, The Lancet. Oncology.

[5] David Green,et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.

[6] Y. Hirose,et al. Progressive Multifocal Leukoencephalopathy in a Patient with X-linked Agammaglobulinemia , 2003, Scandinavian journal of infectious diseases.

[7] F. Bolgert,et al. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). , 1999, Hematology and cell therapy.